Therapy of Core Binding Factor Acute Myeloid Leukemia: Incremental Improvements Toward Better Long-Term Results

    loading  Checking for direct PDF access through Ovid

Abstract

Micro-Abstract

Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor AML leaves room for substantial improvement. We discuss treatments that have improved outcome in this group of patients with AML and ongoing/future strategies that might contribute toward incremental gains.

Background

Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement.

Materials and Methods

We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts.

Results

Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer.

Conclusions

Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.

Related Topics

    loading  Loading Related Articles